Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer - European Medical Journal

Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer

Oncology
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b clinical trial that evaluated the safety and clinical activity of avelumab, a fully human anti-PD-L1 IgG1 antibody, for the treatment of patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.